www.hhs.gov U.S. Department of Health and Human Services

The Safety Evaluation and Surveillance of Generic Drugs

Step Status
Educational Content
Starts On: Fri, 2/3/23: 12:00 AM EST
Ends On: Wed, 12/31/25: 12:00 AM EST
Type: Enduring Material
Credits: 1.5
Description: In the United States, 9 out of 10 prescriptions filled are for generic drugs. The Office of Generic Drugs (OGD) within the Center for Drug Evaluation and Research (CDER) follows a rigorous review process to ensure drug products that are approved in Abbreviated New Drug Applications (ANDAs) are of high quality, safe and considered by FDA to be therapeutically equivalent to their Reference Listed Drug (RLD).

This webinar provides health care professionals with information on the evaluations performed, methods, and tools used by OGD's Office of Safety and Clinical Evaluation (OSCE) to assess the safety and effectiveness of generic drugs throughout the life-cycle of the product (e.g., pre-market and post-market setting).
  • Review the methods used by FDA to monitor the safety and effectiveness of generic drugs in the pre-market and post-market setting
  • Identify scenarios and approaches when OGD Pharmacology/Toxicology assesses the safety of excipients in generic drug products
  • Describe the sources of drug impurities and how OGD Pharmacology/Toxicology assesses their safety in generic drug products and drug master files
  • Recognize how comparative clinical studies and other assessments are used to evaluate the bioequivalence and comparative safety of new potential generic drug products
Additional Information: Review the Activity Announcement for additional details: Announcement Form

Additional Resources: Slides
ACCME Joint Accreditation
  • This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
  • This system is provided for Government-authorized use only.
  • Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
  • Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
  • By using this system, you understand and consent to the following:
    • The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
    • Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.